Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1

Kawai, Akira; Naito, Noriko; Yoshida, Aki; Morimoto, Yuki; Ouchida, Mamoru; Shimizu, Kenji; Beppu, Yasuo

doi:10.1016/j.canlet.2003.09.031

Cited by 102 publications

(83 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1A), consistent with the previous studies that the epithelial components in biphasic synovial sarcoma highly express c-Met (39). Following HGF stimulation, the tyrosine-phosphorylated form of c-Met became detectable in all cell lines (Fig.…”

Section: Hgf-induced Tyrosine Phosphorylation Of C-met and Gab1 In Husupporting

confidence: 91%

Adaptor Molecule Crk Is Required for Sustained Phosphorylation of Grb2-Associated Binder 1 and Hepatocyte Growth Factor–Induced Cell Motility of Human Synovial Sarcoma Cell Lines

Watanabe

Tsuda

Makino

et al. 2006

Molecular Cancer Research

View full text Add to dashboard Cite

Activation of the c-Met receptor tyrosine kinase through its ligand, hepatocyte growth factor (HGF), promotes mitogenic, motogenic, and morphogenic cellular responses. Aberrant HGF/c-Met signaling has been strongly implicated in tumor cell invasion and metastasis. Both HGF and its receptor c-Met have been shown to be overexpressed in human synovial sarcoma, which often metastasizes to the lung; however, little is known about HGF-mediated biological effects in this sarcoma. Here, we provide evidence that Crk adaptor protein is required for the sustained phosphorylation of c-Met-docking protein Grb2-associated binder 1 (Gab1) in response to HGF, leading to the enhanced cell motility of human synovial sarcoma cell lines SYO-1, HS-SY-II, and Fuji. HGF stimulation induced the sustained phosphorylation on Y307 of Gab1 where Crk was recruited. Crk knockdown by RNA interference disturbed this HGF-induced tyrosine phosphorylation of Gab1. By mutational analysis, we identified that Src homology 2 domain of Crk is indispensable for the induction of the phosphorylation on multiple Tyr-X-X-Pro motifs containing Y307 in Gab1. HGF remarkably stimulated cell motility and scattering of synovial sarcoma cell lines, consistent with the prominent activation of Rac1, extreme filopodia formation, and membrane ruffling.

show abstract

Section: Hgf-induced Tyrosine Phosphorylation Of C-met and Gab1 In Husupporting

confidence: 91%

Adaptor Molecule Crk Is Required for Sustained Phosphorylation of Grb2-Associated Binder 1 and Hepatocyte Growth Factor–Induced Cell Motility of Human Synovial Sarcoma Cell Lines

Watanabe

Tsuda

Makino

et al. 2006

Molecular Cancer Research

View full text Add to dashboard Cite

show abstract

“…For the in vivo studies, the mouse osteosarcoma LM8 (23), human osteosarcoma SaOS2 (24), human fibrosarcoma HT1080 (25), human synovial sarcoma Syo-1 (26), human renal cancer 786-O (27), human prostate cancer PC-3 (28) and human lung cancer A549 (29) cell lines were used. LM8, SaOS2, Syo-1, 786-O, and A549 cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Nacalai Tesque, Inc., Kyoto, Japan) containing 10% fetal calf serum (FCS) (Nacalai Tesque, Inc.) and 100 U/ml penicillin G and 100 mg/ml streptomycin antibiotics (Nacalai Tesque, Inc.).…”

Section: Methodsmentioning

confidence: 99%

Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors

et al. 2017

View full text Add to dashboard Cite

Abstract. Metastatic and primary bone tumors are malignant tumors affecting the skeleton. Although the prognosis of patients with these tumors has improved with the development of effective chemotherapy, the challenges of local recurrence, subsequent osteolysis, degradation of bone strength and unresectable tumors persist. Local control of these tumors is therefore a key strategy to address these limitations. The third-generation bisphosphonate (BP), zoledronic acid (ZOL), has been demonstrated to reduce osteoclasts and exhibited potent antitumor effects in a number of malignancies. Hydroxyapatite (HA) and polymethyl methacrylate (PMMA) bone cement are used in orthopedic surgery as bone graft substitutes, for implant arthroplasty and bone strengthening, and as a sustained-release system for drugs such as antibiotics. At present, the antitumor effects of ZOL-loaded HA in vitro or in vivo or of ZOL-loaded bone cement in vivo have not been described. Therefore, the present study assessed the effects of ZOL-loaded HA and bone cement in malignant tumor cells. The two materials exerted strong antitumor effects against osteosarcoma, fibrosarcoma, synovial sarcoma, renal cancer, prostate cancer and lung cancer cells upon releasing ZOL. The antitumor effects of ZOL-loaded HA were less potent compared with those of ZOL-loaded bone cement, possibly as BPs exhibit higher affinity to HA. ZOL-loaded bone cement also exerted antitumor effects against pulmonary metastases and primary lesions, without exhibiting systemic toxicity in vivo. These results demonstrate that these materials may be beneficial for the treatment of malignant bone tumors, including metastatic bone tumors. In addition, as these materials are already in clinical use, such applications may be easily implemented.

show abstract

“…The following sarcoma derived cell-lines were used: Ewing sarcoma: L1062, EW7 25 , IOR/BRZ which was kindly provided by Katia Scotlandi, CRS Laboratory of Experimental Oncology-Rizzoli Orthopaedic Institute, 26 Sk-N-MC, STA-ET2.1, RD-ES, CADO-ES, A673, TC71, SK-ES1 and EW3; 27 osteosarcoma: Saos-2, HOS143b, SJSA1, U2-OS, ZK58, MG63 and OHS; 27 rhabdomyosarcoma: RD (ATCC: HTB-166), RH30, A204 and TE671 (DSMZ: ACC-489, ACC-250 and ACC-263, respectively) and from synovial sarcoma: SYO-1, which was a kind gift from Akira Kaway, National Cancer Center Hospital, Tokyo. 28 …”

Section: Methodsmentioning

confidence: 99%

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy

et al. 2018

View full text Add to dashboard Cite

Synovial sarcoma expresses multiple cancer testis antigens that could potentially be targeted by T-cell receptor (TCR) gene therapy. In this study we investigated whether PRAME-TCR-gene therapy could be an effective treatment for synovial sarcoma by investigating the potential of PRAME-specific T-cells to recognize sarcoma cells and by evaluating the expression patterns of PRAME and HLA class I (HLA-I) in synovial sarcoma tumor samples. All PRAME expressing sarcoma cell lines, including 2 primary synovial sarcoma cell cultures (passage < 3), were efficiently recognized by PRAME-specific T-cells. mRNA FISH demonstrated that PRAME was expressed in all synovial sarcoma samples, mostly in an homogeneous pattern. Immunohistochemistry demonstrated low HLA-I baseline expression in synovial sarcoma, but its expression was elevated in specific areas of the tumors, especially in biphasic components of biphasic synovial sarcoma. In 5/11 biphasic synovial sarcoma patients and in 1/17 monophasic synovial sarcoma patients, elevated HLA-I on tumor cells was correlated with infiltration of T-cells in these specific areas. In conclusion, low-baseline expression of HLA-I in synovial sarcoma is elevated in biphasic areas and in areas with densely infiltrating T-cells, which, in combination with homogeneous and high PRAME expression, makes synovial sarcoma potentially a suitable candidate for PRAME-specific TCR-gene therapy.

show abstract

Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1

Cited by 102 publications

References 23 publications

Adaptor Molecule Crk Is Required for Sustained Phosphorylation of Grb2-Associated Binder 1 and Hepatocyte Growth Factor–Induced Cell Motility of Human Synovial Sarcoma Cell Lines

Adaptor Molecule Crk Is Required for Sustained Phosphorylation of Grb2-Associated Binder 1 and Hepatocyte Growth Factor–Induced Cell Motility of Human Synovial Sarcoma Cell Lines

Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy

Contact Info

Product

Resources

About